Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD44 in rheumatoid arthritis.

David Naor1, Shlomo Nedvetzki

  • 1Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem, Israel. naord@md2.huji.ac.il

Arthritis Research & Therapy
|May 2, 2003
PubMed
Summary

CD44, a cell-surface glycoprotein, plays a role in rheumatoid arthritis (RA) inflammation. Targeting CD44 with antibodies reduced arthritis symptoms in mice, suggesting therapeutic potential for RA patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A short peptide protects from age-onset proteotoxicity.

Aging cell·2023
Same author

Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine.

International journal of toxicology·2023
Same author

Potent antibacterial activity in surgical wounds with local administration of D-PLEX<sub>100</sub>.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2023
Same author

MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A.

Journal of autoimmunity·2021
Same author

D-PLEX<sub>100</sub> in an Abdominal Surgery Incision Model in Miniature Swine: Safety Study.

Toxicologic pathology·2020
Same author

Editorial: Cell-Cell and Cell-Matrix Adhesion in Immunobiology and Cancer.

Frontiers in immunology·2020

Area of Science:

  • Cell Biology
  • Immunology
  • Rheumatology

Background:

  • CD44 is a cell-surface glycoprotein with numerous isoforms generated by alternative splicing.
  • CD44 interacts with ligands like hyaluronic acid (HA) and is crucial for cell migration and growth factor presentation.
  • CD44 is implicated in both normal physiological functions and pathological processes, including cancer and inflammation.

Purpose of the Study:

  • To review the role of CD44 and its ligand HA in rheumatoid arthritis (RA).
  • To evaluate the therapeutic potential of anti-CD44 monoclonal antibodies (mAbs) in preclinical models of arthritis.
  • To explore the challenges in targeting CD44 for RA treatment in patients.

Main Methods:

  • Review of existing literature on CD44 expression and function in RA.
  • In vivo studies using mouse models of collagen- or proteoglycan-induced arthritis treated with anti-CD44 mAbs.
  • In vitro experiments assessing the effect of anti-CD44 mAbs on RA synovial fibroblast migration and matrix interaction.

Main Results:

  • Significant amounts of various CD44 isoforms and HA are present in the synovium of RA patients.
  • Anti-CD44 mAbs targeting constant epitopes reduced inflammatory activity in mouse arthritis models.
  • Anti-CD44 mAbs inhibited RA synovial fibroblast migration and their destructive interaction with cartilage matrix in vitro.

Conclusions:

  • CD44 is a key player in RA pathogenesis, mediating inflammatory cell localization, migration, and matrix degradation.
  • Targeting CD44 with specific mAbs shows promise for treating RA by reducing inflammation and joint destruction.
  • Developing strategies to selectively target CD44 in pathological cells while sparing normal cells is crucial for clinical translation in RA therapy.

Related Experiment Videos